Exploring Afamelanotide for Vitiligo: Insights into the CUV 105 Phase 3 Clinical Trial
Tareen Dermatology partners with CLINUVEL for phase 3 CUV 105 trial evaluating afamelanotide plus NB-UVB phototherapy for vitiligo, targeting Fitzpatrick skin types IV-VI. The study aims to assess superior repigmentation compared to NB-UVB monotherapy, with afamelanotide administered as a 16 mg subcutaneous implant every 3 weeks for 5 months, followed by a 6-month follow-up. Previous phase 2 results showed faster and more significant repigmentation with combination therapy, though challenges include patient eligibility and potential adverse effects like diffuse hyperpigmentation.
Related Clinical Trials
Reference News
Tareen Dermatology partners with CLINUVEL for phase 3 CUV 105 trial evaluating afamelanotide plus NB-UVB phototherapy for vitiligo, targeting Fitzpatrick skin types IV-VI. The study aims to assess superior repigmentation compared to NB-UVB monotherapy, with afamelanotide administered as a 16 mg subcutaneous implant every 3 weeks for 5 months, followed by a 6-month follow-up. Previous phase 2 results showed faster and more significant repigmentation with combination therapy, though challenges include patient eligibility and potential adverse effects like diffuse hyperpigmentation.